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Abstract
Introduction In patients, a transient decrease in peripheral 
blood lymphocyte counts was observed following intra-
peritoneal administration of the trifunctional monoclonal 
antibody catumaxomab (anti-human EpCAM x anti-human 
CD3). The aim of this study was to clarify the observed ef-
fect in a preclinical mouse model and to analyse the related 
mechanism of action in vitro.
Materials and methods A related antibody, BiLu (anti-
human EpCAM x anti-mouse CD3), was administered to 
mice and blood leukocytes were analysed. In vitro stud-
ies measured activation and cytokine secretion from hu-
man peripheral blood mononuclear cells (PBMC). For the 
analysis of T cell adhesion, PBMC were preincubated with 
catumaxomab and then co-cultured with human endothelial 
cells (HUVEC); T cell adhesion was assessed in the pres-
ence or absence of endothelial cell preactivation by TNF. 
Adherent T cells were determined by fl ow cytometry.
Results Treatment of mice with BiLu resulted in a dose-
dependent transient decrease in CD3+ T cells (both CD4+ 
and CD8+) that returned to the normal range within 48 h. 
Catumaxomab physiologically activated T cells in vitro 
(increased CD69 expression) and induced cytokine release 
(TNF, IFN). TNF increased expression of adhesion 
molecules CD54 and CD62E on endothelial cells. Further-
more, catumaxomab dose-dependently enhanced adhe-
sion of T cells to endothelial cells. Adhesion was further 
increased when endothelial cells were preactivated with 
TNF. 
Conclusions Catumaxomab increases adhesion of T cells 
to endothelial cells due to antibody-mediated activation of 
T cells and production of T cell cytokines that up-regulate 
endothelial cell adhesion molecules. These results provide 
a mechanistic rationale for the transient, reversible de-
crease in lymphocyte counts observed following catumax-
omab administration in patients, which is likely to be due 
to redistribution of lymphocytes. 
Keywords Catumaxomab · Trifunctional antibody ·
T lymphocyte · Endothelium · Adhesion · Redistribution 
Introduction
Catumaxomab is a trifunctional monoclonal antibody of 
mouse IgG2a and rat IgG2b origin. It is indicated for the 
intraperitoneal (i.p.) treatment of malignant ascites in pa-
tients with epithelial cancer [1, 2]. The antibody targets 
human CD3 (expressed on T lymphocytes) and EpCAM 
(human epithelial cell adhesion molecule), a tumour-asso-
ciated antigen, and possesses a third functional binding site 
in its Fc-region, which preferentially binds and activates 
activating Fc-receptor-positive accessory cells. Thus, 
binding of catumaxomab to EpCAM-positive tumour cells 
results in simultaneous recruitment and activation of both 
T lymphocytes and Fc-receptor-positive accessory cells at 
the tumour site. The tumour cells and immune effector cells 
are brought into close proximity, and a complex “crosstalk” 
between T cell and accessory cell can occur resulting in ef-
fective killing of tumour cells [3–5]. Thus, catumaxomab 
leads to physiological cellular activation, cytokine release 
and proliferation of T cells.
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In patients a transient decrease in peripheral blood 
lymphocyte counts was observed following catumaxomab 
infusion [1, 2, 6]. Normalisation mostly occurred within 
2–3 days after treatment. Due to the transient nature of the 
lymphocyte reduction and due to the observed short recov-
ery period this reversible decrease is attributed to a redistri-
bution of lymphocytes. 
T lymphocytes are able to extravasate, migrate into 
organ parenchyma and re-appear in the circulation via the 
lymphatic system [7]. They can redistribute from the intra-
vascular pool to the extravascular pool (e.g., bone marrow, 
spleen, lymph nodes, etc.). Activation of T lymphocytes re-
sults in up-regulation of adhesion molecules and increased 
cytokine production. The increased levels of T lymphocyte 
cytokines, such as tumour necrosis factor alpha (TNF) 
and interferon gamma (IFN), up-regulate expression of 
endothelial cell adhesion molecules. This leads to increased 
adhesion of lymphocytes to endothelium and migration into 
the extravascular space [8, 9].
By contrast, lymphocytopenia due to decreased produc-
tion or increased destruction of lymphocytes can persist for 
months to years after therapy [7, 10, 11]. Lymphocytopenia 
is defi ned as a lymphocyte count of 1.0109/l. In periph-
eral blood, approximately 65–80% of lymphocytes are T 
cells and 8–15% are B cells, so lymphocytopenia is more 
likely to be associated with changes in the T cell count. 
Lymphocytopenia may be a result of decreased production 
of lymphocytes (e.g., due to inherited immunodefi ciency 
or zinc defi ciency), increased destruction of lymphocytes 
(e.g., due to radiotherapy, chemotherapy, HIV), redistri-
bution of lymphocytes (e.g., due to steroids, anaesthesia, 
surgery, infections), or various unknown or multifactorial 
pathogeneses [7]. 
The aim of this study was to determine whether the 
transient lymphocyte decrease following catumaxomab 
administration might be due to antibody-induced adhesion 
of lymphocytes. We conducted an in vivo study in mice to 
evaluate the effect of CD3 binding by the closely related 
trifunctional antibody BiLu (anti-human EpCAM x anti-
mouse CD3) on lymphocytes. In addition, in vitro studies 
investigated the effect of catumaxomab on human T cell ac-
tivation, cytokine release and adhesion to endothelial cells.
Materials and methods
Effect on lymphocytes in vivo
The trifunctional antibody BiLu (anti-human EpCAM x 
anti-mouse CD3; TRION Research GmbH) binds to mouse 
CD3. Female BALB/c mice (Elevage Janvier, France) 
received intravenous (i.v.) doses of BiLu (diluted in PBS) 
as bolus application of 10 ml/kg. Mice (48 per dose group 
with 6 per time point) received single doses of 0 (vehicle 
control), 30, 100 or 300 µg/kg. Blood samples were taken 
from all mice before BiLu administration and a second 
sample was taken either at 4, 8, 16, 24, 48, 72, 96 or 120 
h after administration. CD3, CD4, CD8 and CD45+ leu-
kocytes were measured by fl ow cytometry (Coulter EPICS 
XL/MCL, Beckman Coulter, Germany) using monoclonal 
rat-anti-mouse antibodies (BD Pharmingen, Germany): 
CD45-PECy5/CD3-FITC/CD4-PE, CD45-PE-Cy5/CD3-
FITC/CD8-PE and CD3-FITC/CD4-PE/CD8-PE-Cy5. The 
mean fl uorescence of the CD3 staining was comparable in 
samples after vehicle or BiLu administration, which con-
fi rms that binding of BiLu did not affect the detection of T 
cells by the anti-CD3 antibodies used in this study.
T cell preparation and activation in vitro
Peripheral blood mononuclear cells (PBMC) from healthy 
donors were isolated from EDTA-blood by density gradi-
ent centrifugation. PBMC (106 cells/ml) were incubated in 
RPMI-1640 (Gibco/Invitrogen, Germany) plus 10% foetal 
bovine serum (Sigma-Aldrich, Germany) in the presence or 
absence of catumaxomab (2–200 ng/ml; Fresenius Biotech 
GmbH, Germany) for 24 h at 37°C. The cells were harvested, 
washed with phosphate-buffered saline (PBS), stained with 
anti-CD69-PE (Becton Dickinson, Germany) together with 
the T cell marker anti-CD3-FITC (Becton Dickinson), and 
analysed by fl ow cytometry (FACSCalibur, BD Bioscience). 
Cytokine secretion from T cells in vitro
PBMC (105 cells) were co-cultured with EpCAM-positive 
HCT-8 tumour cells (104 cells) in the presence or absence 
of catumaxomab (0.1–20 ng/ml; Fresenius Biotech GmbH, 
Germany) for 20 h at 37°C. Cell culture supernatants were 
collected and analysed for catumaxomab-induced TNF 
and IFN release using a cytometric bead array (CBA Cy-
tokine Kit II; Becton Dickinson) according to the manufac-
turer’s instructions. 
Endothelial cell preparation and activation in vitro
Human vascular endothelial cells (HUVEC) were iso-
lated from umbilical vein following informed consent. The 
umbilical vein (within 24 h after birth) was fl ushed with 
PBS, fi lled with 0.02% collagenase (Sigma-Aldrich) buf-
fer, incubated for 12 min at 37°C, and cells were collected 
and cultured in ECGM-Medium (Promocell, Germany) at 
37°C. The cells were sub-cultured to a maximal passage 
number of 5 before use. HUVEC were incubated in the 
presence or absence of 25 ng/ml TNF (Sigma-Aldrich) 
for 24 h before analysis. 
For analysis of adhesion molecule expression, HU-
VEC were detached with 1 mM EDTA, washed twice with 
PBS, stained with anti-CD62E-FITC (Becton Dickinson), 
anti-CD54-FITC (Becton Dickinson) and anti-CD31-FITC 
(Dianova, Germany), and analysed by flow cytometry 
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(FACSCalibur). A multiparametric analysis was carried 
out to detect expression of CD62E and CD54 by CD31+ 
endothelial cells.
T cell adhesion to endothelial cells in vitro
Analysis of adhesion of T cells to endothelial cells was per-
formed using co-cultures of PBMC and adherent HUVEC. 
PBMC were preincubated with catumaxomab (2–200 
ng/ml) for 24 h. Subconfluent monolayers of HUVEC 
in 6-well plates were preincubated in the absence/pres-
ence of TNF for 24 h. Following preincubation, PBMC 
(2106 cells/well) were transferred to the HUVEC cultures 
and incubated for 2 h at 37°C. Non-adherent cells were 
removed by extensive washing; and adherent PBMC and 
HUVEC were detached using trypsin/EDTA (Invitrogen). 
The relative amount of T cells (CD3+) attached to HUVEC 
(CD31+) was determined by fl ow cytometry (FACSCalibur, 
BD Bioscience). 
Results
Effect on lymphocytes in vivo
Female BALB/c mice (48 per group, 6 per time point) re-
ceived i.v. doses of BiLu, a trifunctional antibody (anti-hu-
man EpCAM x anti-mouse CD3) that binds to mouse CD3. 
The relative amount of total CD3+ cells was comparable 
in all groups of mice before application of BiLu (44–52% 
of total CD45+ leukocytes). Application of vehicle control 
(phosphate-buffered saline) resulted in no relevant change 
in the relative amount of CD3+ cells (mean 43%). 
The investigation of the effect of CD3-binding on 
peripheral blood lymphocytes revealed that treatment of 
BALB/c mice with BiLu resulted in dose-dependent tran-
sient decreases in T cell counts (Fig. 1). A dose-dependent 
transient decrease in total CD3+ T cells (% of total CD45+ 
leukocytes) was apparent 4 h after application of BiLu and 
persisted up to 24 h, after which CD3+ cells returned to 
baseline values within 48 h (Fig. 1A). At 4–8 h after appli-
cation of 30, 100 or 300 µg/kg BiLu, the CD3+ T cells de-
clined to levels of 17–18%, 4–5% and 2–4%, respectively 
(control 39–46%). 
Figures 1B and 1C show the effect of BiLu on CD4+ 
and CD8+ T cell subsets (% of total CD3+ T cells). There 
was no relevant effect of 30 µg/kg BiLu compared to vehi-
cle control: throughout the experiment (up to 120 h), CD4+ 
levels were 70–75% vs. 72–79% in control and CD8+ lev-
els were 20–28% vs. 22–26% in control. At higher doses 
of BiLu, 100 and 300 µg/kg, the relative amount of both 
CD4+/CD3+ and of CD8+/CD3+ cells decreased. As with 
CD3+ T cells, there was a dose-dependent decrease in the 
proportion of CD4+/CD3+ cells up to 8–24 h post-appli-
cation of 100 or 300 µg/kg BiLu (to a minimum of 44% 
and 15%, respectively), after which the levels of these cells 
slowly increased back to normal levels after 48 h. There 
was a similar transient decrease in the relative amount of 
Fig. 1 Effect of BiLu (anti-human EpCAM x anti-mouse CD3) on T 
cells in mice. A CD3+ T cells as a % of total leukocytes (CD45+). B 
CD4+CD3+ T cells as a % of total T cells (CD3+). C CD8+CD3+ T 
cells as a % of total T cells (CD3+). Groups of female BALB/c mice 
received i.v. doses of BiLu in a bolus application of 10 ml/kg at doses 
of 0, 30, 100 or 300 µg/kg. Blood samples (0.2 ml) were taken from 
all mice before administration of BiLu and a single sample was taken 
from each mouse at 4, 8, 16, 24, 48, 72, 96 or 120 h after the last ap-
plication. CD3+, CD4+, CD8+ and CD45+ leukocytes were measured 
by fl ow cytometry. Data are shown as mean values from 6 animals per 
time point (48 animals at time 0)
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CD8+/CD3+ cells in animals treated with 100 or 300 µg/
kg BiLu (to a minimum of 13% and 9%, respectively) that 
persisted for 24 h, after which the levels rebounded to val-
ues greater than baseline (to 38% and 46%, respectively) 
before recovering to baseline values by 48 h. 
Overall, treatment of mice with BiLu resulted in only a 
transient decrease in CD3+ T cells (both CD4+ and CD8+) 
that returned to the normal range, mostly within 48 h.
Effects of catumaxomab on T cell activation and cytokine 
secretion in vitro
Next, we addressed the effect of catumaxomab on human 
T cell activation and cytokine secretion. Table 1 shows that 
incubation of PBMC for 24 h with 2, 20 and 200 ng/ml ca-
tumaxomab increased expression of the activation marker 
CD69 on T cells. Figure 2 shows that incubation of PBMC 
with tumour target cells (EpCAM-positive HCT-8 cells) 
and catumaxomab (0.1 to 20 ng/ml) resulted in a concen-
tration-dependent increase in secretion of both TNF (Fig. 
2A) and IFN (Fig. 2B). 
Effect of TNF on endothelial cell activation in vitro
Then, the effect of TNF on HUVEC activation was inves-
tigated. Table 2 shows that incubation of HUVEC for 24 h 
with 25 ng/ml TNF increased expression of the adhesion 
molecules CD54 and CD62E on HUVEC. Although there 
were variations between donors, the number of positive 
cells and the expression level (mean fl uorescence intensity, 
MFI) of these adhesion markers markedly increased com-
pared to control without TNF.
Effect of catumaxomab on T cell adhesion to endothelial 
cells in vitro
Figure 3 shows that activation of T cells by catumax-
omab (2–200 ng/ml) resulted in a concentration-depen-
Table 1 Effect of catumaxomab on CD69 expression on human T cells






Human PBMC were incubated with catumaxomab for 24 h and CD69 
expression was determined by fl ow cytometry
n, number of independent donors; SE, standard error
Fig. 2 Effect of catumaxomab on cytokine secretion from PBMC in 
vitro. A TNF secretion; B IFN secretion. PBMC were co-cultured 
with EpCAM-positive HCT-8 tumour cells for 20 h at 37°C. Cell 
culture supernatants were collected and analysed for catumaxomab-
induced TNF and IFN release using a cytometric bead array. The 
limit of quantifi cation was 20 pg/ml. Both cytokines were measured 
in the same samples. Data are shown as mean values±standard error 
from 12 replicates
Table 2 Effect of TNF on expression of activation markers on human umbilical vein endothelial cells
TNF (ng/ml) CD62E  CD54
 % positive cells MFI % positive cells MFI
0 7.0±6.1 27±11 49.9±11.3 288±106
25 38.2±9.7 130±49 75.5±9.0 4138±1385
HUVEC were incubated with TNF for 24 h and adhesion molecule expression was determined by fl ow cytometry. Data are shown as 
mean±standard error from 6 independent donors
MFI, mean fl uorescence intensity
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dent increase in T cell adhesion to endothelial cells. This 
catumaxomab-induced adhesion of T cells was seen in 
the presence or absence of endothelial cell preactivation 
by TNF. Preactivation of endothelial cells with TNF 
induced increased T cell adhesion in the absence of catu-
maxomab, and adhesion was further increased in a concen-
tration-dependent manner when T cells were activated with 
catumaxomab (2 and 20 ng/ml). No clear differences in the 
catumaxomab-induced adhesion between samples with or 
without TNF preactivation were detected at 200 ng/ml. 
Discussion
We have shown that treatment of mice with the trifunction-
al antibody BiLu (anti-human EpCAM x anti-mouse CD3) 
resulted in a dose-dependent transient decrease in CD3+ T 
cells (both CD4+ and CD8+) that returned to the normal 
range, mostly within 48 h. These results are consistent with 
fi ndings of a transient decrease in lymphocyte counts after 
infusion of catumaxomab (anti-human EpCAM x anti-
human CD3) in patients [1, 2, 6]. The decrease observed in 
patients was transient, returning to normal within 2–3 days, 
mild to moderate in intensity and in general fully revers-
ible. Furthermore, there was no increase in the number or 
nature of infections. 
The short recovery interval argues against an antibody-
mediated destruction of lymphocytes. We, therefore, con-
ducted in vitro studies to investigate the potential mecha-
nism behind this adhesion induced by catumaxomab.
We showed that catumaxomab physiologically activates 
T cells (increased expression of CD69) and stimulates the 
release of cytokines, including TNF and IFN, from hu-
man PBMC in vitro. T cell activation was observed starting 
at the lowest concentration of catumaxomab studied (2 ng/
ml) and an increase in cytokine release was observed at 
catumaxomab in vitro concentrations from 0.1 ng/ml. This 
is in accordance with previous in vitro studies which un-
derline that catumaxomab activates PBMC and stimulates 
the release of cytokines, including TNF and IFN, from 
human blood cells in the presence of target tumour cells 
[12–15] as part of its mode of action. Release of TNF and 
IFN peaked at 24 h [14]. Furthermore, a clinical study has 
shown that catumaxomab increases serum TNF in pa-
tients with malignant ascites [6].
Pharmacokinetic data demonstrate systemic availability 
of catumaxomab after intraperitoneal administration with a 
median Cmax of approximately 0.4 ng/ml in plasma. Thus, 
even this low systemic exposure would be suffi cient to ac-
tivate PBMC and increase levels of TNF, which provides 
an explanation for the increased levels of serum TNF ob-
served in catumaxomab-treated patients [6].
We showed that exogenous TNF increases expression 
of adhesion molecules, ICAM-1 (CD54) and E-selectin 
(CD62E) on endothelial cells. Since catumaxomab-acti-
vated PBMC produce TNF, this observation is consistent 
with the hypothesis that cytokines (e.g., TNF) released by 
immune cells due to anti-CD3-antibody binding can acti-
vate endothelial cells, resulting in increased expression of 
adhesion molecules on the endothelial cell surface.
We further showed that catumaxomab dose-dependent-
ly increases adhesion of T cells to endothelial cells and that 
adhesion is further increased when endothelial cells are 
preactivated with TNF. 
These results are supported by previous studies with 
other bispecifi c anti-CD3 antibodies: In vitro studies with a 
related trifunctional antibody (BiUII) showed that antibody-
stimulated production of TNF by PBMC depends on the 
presence of target tumour cells, with approximately four 
times more TNF produced by PBMC in the presence of 
target cells, which contributes to the antitumour activity of 
the antibody [16]. Administration of an EpCAM/CD3-bispe-
cifi c BITE antibody to mice resulted in a transient increase 
in serum levels of TNF and IFN [17]. Another bispecifi c 
anti-CD3 antibody also caused a rapid increase in plasma 
levels of TNF and IFN in carcinoma patients [18, 19]. 
Thus, the transient decrease in lymphocytes observed 
with CD3-binding antibodies is interpreted as an antibody-
induced redistribution phenomenon as a result of adhe-
sion to the endothelial cells and migration from the blood 
stream into the tissues, and possibly into the tumour. 
Peripheral blood lymphocytes isolated from patients 
after administration of monospecific anti-CD3 antibod-
ies had increased expression of T cell adhesion molecules 
(including LFA-1 [CD11a/CD18]) and increased adhesion 
to endothelial cells in vitro [20]. The in vitro adhesion of 
T cells to endothelial cells was mediated by T cell LFA-1 
binding to endothelial cell ICAM-1, and was blocked by 
anti-LFA-1 antibodies. 
Fig. 3 Effect of catumaxomab and TNF on adhesion of human T 
cells to human umbilical vein endothelial (HUVEC) cells. PBMC 
prestimulated with catumaxomab (0–200 ng/ml) were incubated 
with HUVEC prestimulated with TNF for 2 h at 37°C, and adher-
ent T cells were determined by fl ow cytometry. Data are shown as 
mean±standard error from 12 (0 and 20 ng/ml), 9 (2 ng/ml) or 3 (200 
ng/ml) independent experiments with different donors
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An in vitro study showed that preincubation of PBMC 
with a bispecifi c antibody increased adhesion to endothe-
lial cells followed by increased trans-endothelial migration 
[21]. The antibody increased expression of lymphocyte 
adhesion molecules, including VLA-4 and high affin-
ity LFA-1. Furthermore, the antibody-activated PBMC in-
duced expression of endothelial cell adhesion molecules 
(E-selectin, VCAM-1 and ICAM-1) during adhesion and 
trans-endothelial migration. The authors showed that these 
phenomena were related to the CD3-recognising antibody 
fragment of the antibody and were dependent on lympho-
cyte–endothelial cell contact.
Decreases in lymphocyte counts in patients were also 
reported following administration of other anti-CD3 anti-
bodies. Administration of a monospecifi c anti-CD3 anti-
body or polyclonal anti-T cell antibody to patients after re-
nal transplantation resulted in transient decreases in CD3+ 
lymphocyte counts [22]. A further study also showed that 
administration of a monospecific anti-CD3 antibody to 
patients after renal transplantation resulted in decreases in 
lymphocyte counts [20]. Administration of the bispecifi c 
antibody BIS-1 (anti-CD3 x anti-EGP-2) to renal cell carci-
noma patients caused a rapid decrease in circulating mono-
nuclear cells in the peripheral blood [18, 19]. The effect 
was dose-dependent and there was a preferential decrease 
in LFA-1+CD3+/CD8+ lymphocytes [18].
Overall, our results, supported by previous studies, 
demonstrate mechanisms that are involved in anti-CD3 an-
tibody-induced migration of lymphocytes into the tissue. T 
cells that become activated by anti-CD3 antibody binding 
and cytokines (e.g., TNF) released by immune cells due 
to anti-CD3 antibody binding activate endothelial cells 
resulting in increased expression of adhesion molecules on 
the endothelial cell surface. Both mechanisms are likely 
to contribute to the initiation of the adhesion cascade, in-
volving tethering, rolling and fi rm adhesion of T cells to 
endothelial cells; a prerequisite for migration into tissues 
[7–9].
In conclusion, catumaxomab can increase adhesion 
of T cells to endothelial cells, which is due to antibody-
mediated activation of T cells and antibody-mediated 
production of cytokines that up-regulate endothelial cell 
adhesion molecules. These results provide a rationale 
for the transient, reversible decrease in lymphocyte 
counts following catumaxomab administration in pa-
tients, which is likely due to redistribution of lympho-
cytes and not due to damage of circulating lymphocytes 
or stem cells.
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